TORONTO / Feb 01, 2024 / Business Wire / Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of TOTAL30® Multifocal in Canada, the first and only monthly Water Gradient multifocal contact lens that feels like nothing – even at day 30.1
Presbyopia is the gradual decline of the eye’s ability to focus on nearby objects, causing them to appear blurry and out of focus.6 Nearly everyone experiences presbyopia; it is a natural part of aging with most people developing symptoms by their early to mid-40s.6
Many lens wearers stop wearing contact lenses after age 40 due to lens dryness, discomfort and visual acuity issues and often begin wearing bifocals or reading glasses.7 Patients are also on their digital devices more than ever, leading to digital device dryness.8 The new TOTAL30 Multifocal lens helps outsmart digital device dryness by utilizing a proprietary Water Gradient Technology to deliver nearly 100% water at the surface of the lens.9-10
With the introduction of TOTAL30 Multifocal, Alcon continues to launch innovations in fast-growing markets. Data indicate that the multifocal contact lens market is valued over $1 billion globally and growing double digit annually—more rapidly than the contact lens category as a whole.5 With the prevalence of presbyopia reaching 80% by age 45-55, and an increasingly aging population, the category is expected to be poised for continued growth.11 Alcon’s TOTAL30 Multifocal lenses are uniquely positioned within this market, offering Alcon’s premium Water Gradient innovation at an accessible price point of monthly replacement lenses.
“Building on the innovation of DAILIES TOTAL1® Multifocal, the #1 selling Daily Multifocal design in Canada*, TOTAL30 Multifocal will now offer TOTAL comfort and seamless vision at all distances to presbyopic patients who prefer reusable lenses,” said Vanessa Johari Hansen, Country Business Unit Head, Vision Care.1 “With an easy-to-fit design and proven fit success rate, TOTAL30 Multifocal is a win-win for both patients and Eye Care Professionals.”2-4,12
The lens utilizes PRECISION PROFILE® multifocal optical design allowing lens wearers to experience clear, uninterrupted vision at all distances, near through far.12 This is the same optical design found in DAILIES TOTAL1 Multifocal. Data shows that TOTAL30 Multifocal contact lenses are as easy to fit as DAILIES TOTAL1 Multifocal contact lenses.4** In addition, 96% of patients were successfully fit in Alcon Multifocal contact lenses with two simple steps.2-4†
TOTAL30 Multifocal is the third contact lens and latest addition to the TOTAL30 product family. TOTAL30 portfolio also includes TOTAL30 Sphere lenses and TOTAL30 for Astigmatism.
Visit www.myalcon.ca to discover how TOTAL30 Multifocal contact lenses can serve eye care practices and patients with presbyopia.
About TOTAL30® Multifocal Contact Lenses
TOTAL30 Multifocal contact lenses are designed for people with presbyopia and are intended to be used on a monthly replacement schedule. The contact lenses are available with a power range of +6.00 D to + 10.00 D and three ADD powers (Low, Med, High). In Canada, TOTAL30 Multifocal contact lenses are medical devices that must be prescribed by an Eye Care Professional.
See product instructions for complete wear, care, and safety information.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.ca
*Based on daily disposable multifocal contact lens dollar share
**At the initial fitting visit
† With 2 lenses or less per eye, at initial fitting visit
References:
Connect with us on
Facebook
LinkedIn
Last Trade: | US$91.95 |
Daily Change: | -1.32 -1.42 |
Daily Volume: | 569,411 |
Market Cap: | US$45.350B |
August 20, 2024 June 24, 2024 May 13, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB